EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery

Cezary Miedziarek iD, Paweł Caputa, Hubert Bochyński, Mikołaj Piotr Zaborowski iD, Ewa Nowak-Markwitz iD

Cancers · 05.07.2026 · 18 (13) · 2157

DOI: 10.3390/cancers18132157 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.07.2026. Verfasst von Cezary Miedziarek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecological Oncology, Department of Gynecology, Poznan University of Medical Sciences, 61-701 Poznań, Poland. Die Arbeit nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Polish Science, National Agency for Academic Exchange.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytoreductive surgery remains one of the key treatment modalities in advanced ovarian cancer. Complete cytoreduction is the main surgical goal. PARP inhibitors are currently established mainly as maintenance therapy after response to platinum-based chemotherapy, particularly in patients with BRCA-mutated or homologous recombination-deficient tumors. Their use before cytoreductive surgery remains investigational. This review evaluates preoperative PARP inhibition from a surgical perspective. This narrative review summarizes current evidence, ongoing clinical trials, and perioperative considerations related to preoperative or neoadjuvant PARP inhibitor strategies in advanced ovarian cancer. Particular attention was given to the review of current clinical trials’ strategies, resectability, complete cytoreduction, patient selection, perioperative safety, treatment timing, and surgery-specific endpoints. Current studies explore several preoperative approaches, including short window-of-opportunity treatment before primary debulking surgery, PARP inhibitor monotherapy as potential conversion therapy in homologous recombination-deficient disease, PARP inhibitor-based strategies before interval debulking surgery, combination regimens with immunotherapy or antiangiogenic therapy, and preoperative PARP inhibitor use before secondary cytoreduction in recurrent disease. These studies suggest that preoperative PARP inhibition may provide biological and surgical insights, but available evidence remains preliminary. Key concerns include hematologic toxicity, surgical postponement, perioperative complications, wound healing, postoperative recovery, and the risk of delaying standard chemotherapy or surgery. Preoperative PARP inhibitor therapy is theoretically promising but an unproven strategy in ovarian cancer. Its future value will depend on prospective trials showing that it can safely improve resectability and complete cytoreduction without compromising treatment timing. Future studies should include surgery-specific endpoints in addition to conventional oncologic outcomes.

Schlagwörter

Stichwörter der Autor:innen

PARP inhibitorscomplete cytoreductioncytoreductive surgeryneoadjuvant therapyovarian cancer

Autor:innen und Institutionen

  • Division of Gynecological Oncology, Department of Gynecology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
  • Doctoral School, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
  • Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-772 Poznań, Poland.

ORCID-Profile: Cezary Miedziarek, Mikołaj Piotr Zaborowski, Ewa Nowak-Markwitz

Förderung

  • Foundation for Polish Science
  • National Agency for Academic Exchange

Zitieren

APA

Miedziarek, C., Caputa, P., Bochyński, H., Zaborowski, M. P., & Nowak-Markwitz, E. (2026). Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery. Cancers, 18(13), 2157. https://doi.org/10.3390/cancers18132157

Vancouver

Miedziarek C, Caputa P, Bochyński H, Zaborowski MP, Nowak-Markwitz E. Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery. Cancers. 2026;18(13):2157. doi:10.3390/cancers18132157

BibTeX
@article{Miedziarek2026,
  author = {Miedziarek, Cezary and Caputa, Paweł and Bochyński, Hubert and Zaborowski, Mikołaj Piotr and Nowak-Markwitz, Ewa},
  title = {Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {13},
  pages = {2157},
  doi = {10.3390/cancers18132157}
}
Kostenlos starten →